11/20
07:00 am
ucbjy
UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa
Medium
Report
UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa
11/14
12:52 pm
ucbjy
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis [Yahoo! Finance]
Low
Report
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis [Yahoo! Finance]
11/14
12:46 pm
ucbjy
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
Low
Report
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
10/29
07:49 am
ucbjy
Genascence Appoints Jeymi Tambiah as Chief Medical Officer [Yahoo! Finance]
Low
Report
Genascence Appoints Jeymi Tambiah as Chief Medical Officer [Yahoo! Finance]
10/17
11:07 am
ucbjy
Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy [Seeking Alpha]
Low
Report
Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy [Seeking Alpha]
10/11
07:00 am
ucbjy
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
Low
Report
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
10/1
03:59 pm
ucbjy
National Audubon Society Board of Directors Elects Dr. George Golumbeski as Chairman [Yahoo! Finance]
Neutral
Report
National Audubon Society Board of Directors Elects Dr. George Golumbeski as Chairman [Yahoo! Finance]
9/30
07:00 am
ucbjy
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
Low
Report
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
9/27
07:00 am
ucbjy
UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
Low
Report
UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
9/25
07:00 am
ucbjy
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
Low
Report
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
9/23
07:00 am
ucbjy
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Low
Report
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
9/10
11:39 am
ucbjy
STXBP1 Encephalopathy Market Assessment 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
Low
Report
STXBP1 Encephalopathy Market Assessment 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
9/9
01:00 am
ucbjy
New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease
Low
Report
New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease